Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corp

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BillionToOne, Inc. Class A (BLLN) and Bio-Techne (TECH). BillionT...

Analysts Have Conflicting Sentiments on These Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Bio-Techne (TECH)

Tech Mahindra Limited ( ($IN:TECHM) ) has provided an announcement. Tech Mahindra has approved the allotment of 112,907 fully paid equity shares wi...

Current Quarter	$0.49	Next Quarter	$0.4
Current Year	$1.69	Next Year	$1.83
QoQ Growth	-18.4%	YoY Growth	+8.3%
3Y EPS CAGR	-35.2%	Target Price	$63.75
Consensus	Buy	Upside	+32.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TECH	$48.30	+0.19%	1.61M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TECH	$48.30	+0.2%	1.61M
3
4
5
6

TECH

TECH

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Bio-Techne Corp Data in Excel

Get Bio-Techne Corp Data in Excel